BRPI0511504A - composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides - Google Patents

composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides

Info

Publication number
BRPI0511504A
BRPI0511504A BRPI0511504-3A BRPI0511504A BRPI0511504A BR PI0511504 A BRPI0511504 A BR PI0511504A BR PI0511504 A BRPI0511504 A BR PI0511504A BR PI0511504 A BRPI0511504 A BR PI0511504A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
amyloids
preventive
Prior art date
Application number
BRPI0511504-3A
Other languages
English (en)
Inventor
Teiji Kimura
Koki Kawano
Eriko Doi
Noritaka Kitazawa
Kogyoku Shin
Takehiko Miyagawa
Toshihiko Kaneko
Koichi Ito
Mamoru Takaishi
Takeo Sasaki
Hiroaki Hagiwara
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BRPI0511504A publication Critical patent/BRPI0511504A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

COMPOSTO OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, E, AGENTE PREVENTIVO OU TERAPêUTICO PARA UMA DOENçA RESULTANTE DE BETA-AMILóIDES. Um composto representado pela fórmula (I): (sendo que Ar~ 1~ representa imidazolila opcionalmente substituído por de um a três substituintes; Ar~ 2~ representa um grupo piridinila, pirimidinila, ou fenila opcionalmente substituído por de um a três substituintes; X~ 1~ representa (1) -C<154>C- ou (2) uma dupla ligação opcionalmente substituído, etc.; e R¬ 1~ e R¬ 2¬, cada um, representa alquila C~ 1-6~ opcionalmente substituído, cicloalquila C~ 3-8~, etc.) ou um sal farmaceuticamente aceitável do composto; e um uso do composto ou sal como um medicamento.
BRPI0511504-3A 2004-05-26 2005-05-25 composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides BRPI0511504A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004155790 2004-05-26
JP2004310909 2004-10-26
PCT/JP2005/009537 WO2005115990A1 (ja) 2004-05-26 2005-05-25 シンナミド化合物

Publications (1)

Publication Number Publication Date
BRPI0511504A true BRPI0511504A (pt) 2008-01-22

Family

ID=35450811

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511504-3A BRPI0511504A (pt) 2004-05-26 2005-05-25 composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides

Country Status (16)

Country Link
US (4) US7880009B2 (pt)
EP (2) EP1757591A4 (pt)
JP (1) JP4101852B2 (pt)
KR (2) KR101128065B1 (pt)
CN (1) CN101723900B (pt)
AU (1) AU2005247746B2 (pt)
BR (1) BRPI0511504A (pt)
CA (1) CA2566094A1 (pt)
HK (1) HK1103397A1 (pt)
IL (2) IL179374A (pt)
MX (1) MXPA06013534A (pt)
MY (1) MY149038A (pt)
NZ (1) NZ551144A (pt)
RU (1) RU2361872C2 (pt)
TW (1) TWI335816B (pt)
WO (1) WO2005115990A1 (pt)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH072667U (ja) * 1993-06-11 1995-01-13 日産ディーゼル工業株式会社 車両用多段変速装置
WO2002060446A1 (en) 2001-01-29 2002-08-08 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
CZ2006427A3 (cs) 2003-12-29 2006-11-15 Sepracor Inc. Pyrrolové a pyrazolové inhibitory DAAO
WO2005115990A1 (ja) * 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. シンナミド化合物
CN100577657C (zh) * 2004-10-26 2010-01-06 卫材R&D管理有限公司 肉桂酰胺化合物的无定形物
US20060241038A1 (en) * 2005-04-20 2006-10-26 Eisai Co., Ltd. Therapeutic agent for Abeta related disorders
JP2009500425A (ja) 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
WO2007029629A1 (ja) * 2005-09-06 2007-03-15 Shionogi & Co., Ltd. Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
WO2007058304A1 (ja) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. シンナミド化合物の塩またはそれらの溶媒和物
US20090270623A1 (en) * 2005-11-18 2009-10-29 Naoyuki Shimomura Process for production of cinnamide derivative
CA2629745A1 (en) * 2005-11-24 2007-05-31 Eisai R & D Management Co., Ltd. Morpholine type cinnamide compound
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
US20070117839A1 (en) * 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
EA014245B1 (ru) * 2005-12-14 2010-10-29 Бристол-Маерс Сквибб Компани Аналоги арилпропионамида, арилакриламида, арилпропинамида или арилметилмочевины в качестве ингибиторов фактора xia
DE102005062987A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
US20070203111A1 (en) 2006-01-06 2007-08-30 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
ES2566479T3 (es) 2006-01-06 2016-04-13 Sunovion Pharmaceuticals Inc. Inhibidores de reabsorción de monoamina con base en tetralona
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
EA016464B1 (ru) * 2006-03-09 2012-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Полициклические производные арилимидазола
EP2816024B8 (en) 2006-03-31 2018-04-04 Sunovion Pharmaceuticals Inc. Chiral amines
WO2007135970A1 (ja) * 2006-05-19 2007-11-29 Eisai R & D Management Co., Ltd. ヘテロ環系－シンナミド誘導体
CN101448793A (zh) * 2006-05-19 2009-06-03 卫材R&D管理有限公司 脲型肉桂酰胺衍生物
JP2009184924A (ja) * 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
AR062095A1 (es) * 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
JP2008044880A (ja) 2006-08-15 2008-02-28 Bayer Cropscience Ag 殺虫性イソオキサゾリン類
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
WO2008097538A1 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
DE102007009810A1 (de) * 2007-02-28 2008-09-04 Man Roland Druckmaschinen Ag Übertragungsform für einen Übertragungszylinder einer Druckmaschine
TW200848054A (en) * 2007-02-28 2008-12-16 Eisai R&D Man Co Ltd Two cyclic oxomorpholine derivatives
EP2148673A1 (en) * 2007-04-26 2010-02-03 Eisai R&D Management Co., Ltd. Cinnamide compounds for dementia
RU2009144998A (ru) * 2007-05-07 2011-06-20 Шеринг Корпорейшн (US) Модуляторы гамма-секретазы
CN101675045B (zh) 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 作为β-淀粉样蛋白调节剂的杂芳基苯胺
AU2008250119A1 (en) 2007-05-16 2008-11-20 Eisai R & D Management Co., Ltd. One-pot production process for cinnamide derivative
JP5420534B2 (ja) 2007-05-31 2014-02-19 サノビオン ファーマシューティカルズ インク モノアミン再取り込み阻害薬としてのフェニル置換シクロアルキルアミン
PE20090319A1 (es) * 2007-06-01 2009-03-27 Schering Corp Moduladores de gamma secretasa
JP5495331B2 (ja) * 2007-06-01 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション γセクレターゼ修飾因子
US8242150B2 (en) * 2007-06-13 2012-08-14 Merck Sharp & Dohme Corp. Triazole derivatives for treating alzheimer'S disease and related conditions
US20110053918A1 (en) * 2007-06-29 2011-03-03 Zhaoning Zhu Gamma secretase modulators
EP2185522A1 (en) * 2007-08-06 2010-05-19 Schering Corporation Gamma secretase modulators
KR20100055456A (ko) * 2007-08-31 2010-05-26 에자이 알앤드디 매니지먼트 가부시키가이샤 다환식 화합물
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
US8518975B2 (en) * 2007-09-06 2013-08-27 Merck Sharp + Dohme Corp. Gamma secretase modulators
US20100298381A1 (en) * 2007-09-28 2010-11-25 Schering Corporation Gamma secretase modulators
EP2217604A1 (en) 2007-11-05 2010-08-18 Schering Corporation Gamma secretase modulators
WO2009067493A2 (en) * 2007-11-19 2009-05-28 Envivo Pharmaceuticals, Inc. 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
WO2009073779A1 (en) * 2007-12-06 2009-06-11 Schering Corporation Gamma secretase modulators
JP2011506335A (ja) * 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
CA2708151A1 (en) * 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
WO2009076352A1 (en) * 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
CA2710477A1 (en) 2007-12-20 2009-07-09 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
AU2008340421B2 (en) * 2007-12-21 2013-12-19 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
ES2375919T3 (es) 2008-01-11 2012-03-07 F. Hoffmann-La Roche Ag Moduladores de beta-amiloide.
CA2712095A1 (en) * 2008-01-28 2009-08-06 Eisai R&D Management Co., Ltd. Crystalline cinnamide compounds or salts thereof
CN101952275B (zh) * 2008-02-22 2014-06-18 弗·哈夫曼-拉罗切有限公司 β-淀粉样蛋白的调节剂
US8383629B2 (en) * 2008-02-27 2013-02-26 Vitae Pharmaceuticals, Inc. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1
WO2009108766A1 (en) * 2008-02-29 2009-09-03 Schering Corporation Gamma secretase modulators for the treatment of alzheimer ' s disease
WO2010040661A1 (en) * 2008-10-09 2010-04-15 F. Hoffmann-La Roche Ag Modulators for amyloid beta
EP2356115A1 (en) * 2008-11-06 2011-08-17 Schering Corporation Gamma secretase modulators
EP2367826A4 (en) 2008-11-06 2012-07-04 Astrazeneca Ab MODULATORS OF THE PROTEIN -AMYLOID
CN102209537A (zh) 2008-11-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 杂环γ分泌酶调节剂
JP2012508748A (ja) 2008-11-13 2012-04-12 シェーリング コーポレイション γ−セクレターゼ調節剤
CA2742486A1 (en) 2008-11-13 2010-05-20 Schering Corporation Gamma secretase modulators
US8575150B2 (en) 2008-12-16 2013-11-05 Merck Sharp & Dohme Corp. Triazole derivatives for treatment of Alzheimer's disease
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
CA2747750A1 (en) 2008-12-22 2010-07-01 Theodros Asberom Gamma secretase modulators
AU2009330233A1 (en) 2008-12-22 2011-07-07 Merck Sharp & Dohme Corp. Gamma secretase modulators
EA019685B1 (ru) * 2009-02-06 2014-05-30 Янссен Фармасьютикалз, Инк. Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
CA2753696A1 (en) 2009-02-26 2010-09-02 Noritaka Kitazawa Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
EP2401277A1 (en) 2009-02-26 2012-01-04 Eisai R&D Management Co., Ltd. Salt of tetrahydrotriazolopyridine derivative and crystal thereof
JP5559309B2 (ja) 2009-05-07 2014-07-23 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド γ分泌酵素調節物質としての新規置換インダゾールおよびアザインダゾール誘導体
UY32622A (es) * 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
US20120232108A1 (en) 2009-06-16 2012-09-13 Xianhai Huang Gamma secretase modulators
US20120245158A1 (en) 2009-06-16 2012-09-27 Xianhai Huang Gamma secretase modulators
EP2443121A2 (en) 2009-06-16 2012-04-25 Schering Corporation Gamma secretase modulators
CA2767764A1 (en) 2009-07-13 2011-01-20 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
KR20120050450A (ko) 2009-07-15 2012-05-18 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절제로서의 치환된 트리아졸 및 이미다졸 유도체
WO2011007819A1 (ja) 2009-07-17 2011-01-20 塩野義製薬株式会社 ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬
JP2012176901A (ja) 2009-09-25 2012-09-13 Eisai R & D Management Co Ltd 新規ベンゾニトリル化合物およびその製造方法
CA2784769A1 (en) 2010-01-15 2011-07-21 Janssen Pharmaceuticals, Inc. Novel substituted triazole derivatives as gamma secretase modulators
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
WO2011116287A1 (en) * 2010-03-19 2011-09-22 Purdue Research Foundation Ccr5 modulators for treating hiv
US10570113B2 (en) * 2010-04-09 2020-02-25 Semiconductor Energy Laboratory Co., Ltd. Aromatic amine derivative, light-emitting element, light-emitting device, electronic device, and lighting device
KR20130121076A (ko) * 2010-06-15 2013-11-05 에자이 알앤드디 매니지먼트 가부시키가이샤 Ｈｃｖ 감염증 치료제
BR112013004746A2 (pt) 2010-09-02 2016-06-07 Takeda Pharmaceutical "composto, medicamento, inibidor da produção de beta-amilóide, modulador de gama-secretase, métodos para inibir a produção de beta-amilóide, para modular gama-secretase, e para prevenir ou tratar deficiência cognitiva branda ou mal de alzheimer, e, uso do composto."
MX2013010970A (es) 2011-03-24 2013-10-17 Cellzome Ltd Novedosos derivados de triazolil piperazina y triazolil piperidina sustituidos como moduladores de gamma-secretasa.
WO2012158844A1 (en) 2011-05-17 2012-11-22 Shionogi & Co., Ltd. Heterocyclic compounds
EP2739144A4 (en) * 2011-06-20 2015-04-01 Alzheimer S Inst Of America Inc COMPOUNDS AND ITS THERAPEUTIC USE
ES2555167T3 (es) 2011-07-15 2015-12-29 Janssen Pharmaceuticals, Inc. Nuevos derivados de indol sustituidos como moduladores de gamma secretasa
KR102022716B1 (ko) 2011-07-29 2019-09-18 카리오팜 쎄라퓨틱스, 인코포레이티드 하이드라지드 함유 핵 수송 조절인자 및 이의 용도
BR112014001933A2 (pt) * 2011-07-29 2017-02-21 Karyopharm Therapeutics Inc moduladores de transporte nuclear e usos dos mesmos
EP2752402B1 (en) 2011-08-31 2018-06-27 Showa Denko K.K. Production method for 2-alkenylamine compound
WO2013031839A1 (ja) 2011-08-31 2013-03-07 昭和電工株式会社 ２－アルケニルアミン化合物の製造方法
AU2013202978B2 (en) 2012-01-25 2016-05-19 Novartis Ag Heterocyclic compounds and methods for their use
SI3404027T1 (sl) 2012-05-09 2020-08-31 Biogen Ma Inc. Modulatorji jedrnega transporta in njihova uporaba
JP6106745B2 (ja) 2012-05-16 2017-04-05 ヤンセン ファーマシューティカルズ，インコーポレーテッド （特に）アルツハイマー病の治療に有用な置換３，４−ジヒドロ−２Ｈ−ピリド［１，２−ａ］ピラジン−１，６−ジオン誘導体
AU2013366668B2 (en) 2012-12-20 2017-07-20 Janssen Pharmaceutica Nv Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators
WO2014111457A1 (en) 2013-01-17 2014-07-24 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
KR20150132437A (ko) * 2013-03-15 2015-11-25 액테리온 파마슈티칼 리미티드 항말라리아제로서의 신규의 아크릴아미드 유도체
NO3004079T3 (pt) 2013-06-04 2018-06-16
US9718805B2 (en) 2013-06-04 2017-08-01 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators
WO2014195321A1 (en) 2013-06-04 2014-12-11 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators
DK3492455T3 (da) 2013-06-21 2023-08-14 Karyopharm Therapeutics Inc 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer
US9994558B2 (en) * 2013-09-20 2018-06-12 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
WO2015109109A1 (en) 2014-01-15 2015-07-23 Forum Pharmaceuticals Inc. Fused morpholinopyrimidines and methods of use thereof
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
EP3139942B1 (en) 2014-05-05 2019-12-18 Bioventures, Llc COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
US10071087B2 (en) 2014-07-22 2018-09-11 Bioventures, Llc Compositions and methods for selectively depleting senescent cells
SG10201808624VA (en) 2014-08-15 2018-11-29 Karyopharm Therapeutics Inc Polymorphs of selinexor
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
WO2016201168A1 (en) 2015-06-10 2016-12-15 Forum Pharmceuticals Inc. Oxadiazine compounds and methods of use thereof
MX2018001979A (es) 2015-08-18 2019-04-25 Karyopharm Therapeutics Inc (s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer.
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2017117535A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2017114461A1 (zh) * 2015-12-31 2017-07-06 正大天晴药业集团股份有限公司 一种芦可替尼的合成工艺
WO2017117447A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CN105837497B (zh) * 2016-04-01 2018-05-22 南阳师范学院 4-氨基甲酸酯-3-甲氧基肉桂酸环胺烷基酰胺类化合物、制备方法及其用途
KR102447884B1 (ko) 2016-04-21 2022-09-27 바이오벤처스, 엘엘씨 항-세포자멸적 bcl-2 계열 단백질의 열화를 유도하는 화합물 및 이의 용도
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
WO2018107060A1 (en) 2016-12-09 2018-06-14 Denali Therapeutics Inc. Compounds, compositions and methods
CN106749188B (zh) * 2017-01-23 2019-06-18 南阳师范学院 一种n-(苄基哌啶基)-阿魏酰胺-o-烷基胺类化合物、制备方法及其用途
CN106831574B (zh) * 2017-01-23 2019-07-12 南阳师范学院 N-(1,2,3,4-四氢异喹啉基)-阿魏酰胺-o-烷基胺类化合物和应用
US11485725B2 (en) 2017-12-15 2022-11-01 Auransa Inc. Derivatives of piperlongumine and uses thereof
CN110143893B (zh) * 2018-02-14 2022-11-08 复旦大学 一种能强结合α-突触核蛋白聚集体的化合物、其制备方法及其用途
KR102491260B1 (ko) * 2019-12-26 2023-01-27 연세대학교 산학협력단 피롤리딘 유도체 및 이를 포함하는 베타-아밀로이드 또는 타우 단백질 관련 질병의 예방 또는 치료용 약학 조성물
TW202342425A (zh) 2022-02-28 2023-11-01 日商安斯泰來製藥股份有限公司 芳基炔醯胺衍生物

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1101156A (en) * 1965-09-22 1968-01-31 Hickson & Welch Ltd Triazole derivatives and their use as optical whitening agents
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
FR2314731A1 (fr) 1975-06-19 1977-01-14 Nelson Res & Dev Azacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
DE3689506D1 (de) 1985-10-09 1994-02-17 Shell Int Research Neue Acrylsäureamide.
US4783463A (en) * 1985-10-23 1988-11-08 Rorer Pharmaceutical Corporation Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure
DE3541716A1 (de) 1985-11-26 1987-05-27 Celamerck Gmbh & Co Kg Neue acrylsaeureamide
FI91754C (fi) * 1986-12-02 1994-08-10 Tanabe Seiyaku Co Analogiamenetelmä lääkeaineena käyttökelpoisen imidatsolijohdannaisen valmistamiseksi
IT1205834B (it) * 1987-04-22 1989-03-31 Elbart Derivati tiodiossolanici ad attivita' mucolitica a procedimento per la loro preparazione
FI902321A0 (fi) * 1989-05-19 1990-05-09 Eisai Co Ltd Butensyraderivat.
JPH03206042A (ja) 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
WO1991012237A1 (fr) 1990-02-08 1991-08-22 Eisai Co., Ltd. Derive de sulfonamide de benzene
AU680870B2 (en) 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
GB9402807D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
KR970706242A (ko) 1994-10-04 1997-11-03 후지야마 아키라 우레아 유도체 및 ACAT-억제제로서 그의 용도(Urea derivatives and their use as ACAT-inhibitors)
JPH08283219A (ja) 1995-04-07 1996-10-29 Eisai Co Ltd アラルキルアミノアルキルアミド誘導体
US5804577A (en) 1995-09-12 1998-09-08 Hoffmann-La Roche Inc. Cephalosporin derivatives
AU713247B2 (en) 1995-10-19 1999-11-25 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1997043287A1 (en) 1996-05-10 1997-11-20 Icos Corporation Carboline derivatives
WO1998003166A1 (en) 1996-07-22 1998-01-29 Monsanto Company Thiol sulfonamide metalloprotease inhibitors
JP2001508767A (ja) 1996-12-02 2001-07-03 藤沢薬品工業株式会社 ５―ｈｔ拮抗作用を有するインドール―ウレア誘導体
JP3108997B2 (ja) 1997-03-31 2000-11-13 武田薬品工業株式会社 アゾール化合物、その製造法および用途
WO1998043970A1 (en) 1997-03-31 1998-10-08 Takeda Chemical Industries, Ltd. Azole compounds, their production and their use
JP2001527083A (ja) 1997-12-31 2001-12-25 ザ・ユニバーシティ・オブ・カンザス 第二級および第三級アミン含有薬剤の水溶性プロドラッグおよびその製造方法
GB9816984D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US6235728B1 (en) 1999-02-19 2001-05-22 Bristol-Myers Squibb Company Water-soluble prodrugs of azole compounds
EP1159263A1 (en) 1999-02-26 2001-12-05 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
WO2000051981A1 (en) 1999-03-04 2000-09-08 Nortran Pharmaceuticals Inc. Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics
US20040087798A1 (en) 2000-03-14 2004-05-06 Akira Yamada Novel amide compounds
US20010051642A1 (en) 2000-04-17 2001-12-13 Kyunghye Ahn Method for treating Alzheimer's disease
AU2001254555A1 (en) 2000-04-24 2001-11-07 Merck Frosst Canada & Co Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
CN1257894C (zh) 2000-12-04 2006-05-31 弗·哈夫曼-拉罗切有限公司 作为谷氨酸受体拮抗剂的苯基乙烯基或苯基乙炔基衍生物
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
EP1429763B1 (en) 2001-09-14 2007-05-30 Novo Nordisk A/S NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER
JPWO2003043988A1 (ja) * 2001-11-22 2005-03-10 小野薬品工業株式会社 ピペリジン−２−オン誘導体化合物およびその化合物を有効成分として含有する薬剤
AU2002364549B2 (en) 2001-12-10 2007-11-22 Amgen, Inc Vanilloid receptor ligands and their use in treatments
WO2003053912A1 (en) 2001-12-20 2003-07-03 Bristol-Myers Squibb Company α-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS β-AMYLOID INHIBITORS
JP2003206280A (ja) 2001-12-28 2003-07-22 Takeda Chem Ind Ltd ビアリール化合物およびその用途
GB0207436D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
DE60335635D1 (de) 2002-05-22 2011-02-17 Amgen Inc Aminopyrimidin-derivate zur verwendung als vanilloid-rezeptor-liganden zur behandlung von schmerzen
ES2473581T3 (es) 2002-05-31 2014-07-07 Proteotech Inc. Compuestos, composiciones y métodos para el tratamiento de amiloidosis y sinucleinopat�as tales como la enfermedad de Alzheimer, la diabetes de tipo 2 y la enfermedad de Parkinson
PL373329A1 (en) 2002-07-12 2005-08-22 Sanofi-Aventis Deutschland Gmbh Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
JP2006518738A (ja) 2003-02-12 2006-08-17 トランス　テック　ファーマ，インコーポレイテッド 治療薬としての置換アゾール誘導体
EP1628666B1 (en) 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
AU2004268621C1 (en) 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
JP4698604B2 (ja) 2003-12-22 2011-06-08 ファイザー・インク バソプレシン・アンタゴニストとしてのトリアゾール誘導体
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
JP4898458B2 (ja) 2004-02-12 2012-03-14 トランス テック ファーマ，インコーポレイテッド 置換アゾール誘導体、組成物及び使用方法
WO2005087768A1 (en) 2004-03-09 2005-09-22 Merck & Co., Inc. Hiv integrase inhibitors
WO2005115990A1 (ja) * 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. シンナミド化合物
CN100577657C (zh) 2004-10-26 2010-01-06 卫材R&D管理有限公司 肉桂酰胺化合物的无定形物
US20060241038A1 (en) 2005-04-20 2006-10-26 Eisai Co., Ltd. Therapeutic agent for Abeta related disorders
CN101263116B (zh) * 2005-09-15 2011-12-07 霍夫曼-拉罗奇有限公司 可用作肝肉碱棕榈酰转移酶抑制剂的新型杂双环衍生物
WO2007034282A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
US20090270623A1 (en) * 2005-11-18 2009-10-29 Naoyuki Shimomura Process for production of cinnamide derivative
WO2007058304A1 (ja) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. シンナミド化合物の塩またはそれらの溶媒和物
US20070117839A1 (en) 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
CA2629745A1 (en) 2005-11-24 2007-05-31 Eisai R & D Management Co., Ltd. Morpholine type cinnamide compound
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
EA016464B1 (ru) 2006-03-09 2012-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Полициклические производные арилимидазола
AR062095A1 (es) 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
WO2008097538A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
TW200848054A (en) * 2007-02-28 2008-12-16 Eisai R&D Man Co Ltd Two cyclic oxomorpholine derivatives
RU2009144998A (ru) 2007-05-07 2011-06-20 Шеринг Корпорейшн (US) Модуляторы гамма-секретазы
CN101675045B (zh) 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 作为β-淀粉样蛋白调节剂的杂芳基苯胺
US8242150B2 (en) 2007-06-13 2012-08-14 Merck Sharp & Dohme Corp. Triazole derivatives for treating alzheimer'S disease and related conditions
EP2185522A1 (en) 2007-08-06 2010-05-19 Schering Corporation Gamma secretase modulators
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
EP2401277A1 (en) * 2009-02-26 2012-01-04 Eisai R&D Management Co., Ltd. Salt of tetrahydrotriazolopyridine derivative and crystal thereof
US9737703B2 (en) * 2009-07-10 2017-08-22 Boston Scientific Neuromodulation Corporation Method to enhance afferent and efferent transmission using noise resonance

Also Published As

Publication number Publication date
IL179374A (en) 2013-03-24
MXPA06013534A (es) 2007-05-10
TW200607504A (en) 2006-03-01
RU2361872C2 (ru) 2009-07-20
WO2005115990A1 (ja) 2005-12-08
RU2006146070A (ru) 2008-07-10
EP2261218A3 (en) 2011-06-15
US7880009B2 (en) 2011-02-01
MY149038A (en) 2013-07-15
US7667041B2 (en) 2010-02-23
CN101723900B (zh) 2012-08-22
AU2005247746B2 (en) 2010-11-11
IL179374A0 (en) 2007-03-08
US20090281310A1 (en) 2009-11-12
KR101128065B1 (ko) 2012-04-12
CN101723900A (zh) 2010-06-09
US20080070902A1 (en) 2008-03-20
HK1103397A1 (en) 2007-12-21
KR20090101963A (ko) 2009-09-29
CA2566094A1 (en) 2005-12-08
TWI335816B (en) 2011-01-11
US20110086860A1 (en) 2011-04-14
JPWO2005115990A1 (ja) 2008-03-27
EP2261218A2 (en) 2010-12-15
IL206109A (en) 2013-03-24
US7687640B2 (en) 2010-03-30
JP4101852B2 (ja) 2008-06-18
EP1757591A1 (en) 2007-02-28
EP1757591A4 (en) 2010-05-05
NZ551144A (en) 2009-12-24
US20060004013A1 (en) 2006-01-05
KR20070026648A (ko) 2007-03-08
EP2261218B1 (en) 2013-04-03
KR100966749B1 (ko) 2010-06-30
AU2005247746A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
BRPI0511504A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
EP1679309A4 (en) ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
UA106199C2 (ru) Производные аминобензамида как агенты, пригодные для использования для борьбы с паразитами животных
ME01992B (me) Jedinjenje diarilhidantoina
BRPI0714908B8 (pt) derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende
TW200728307A (en) Novel spirochromanone derivatives
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
BRPI0507944A (pt) composição farmacêutica
FR2903107B1 (fr) Derives d&#39;imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
AR049681A1 (es) Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas
DK1885187T3 (da) Fremgangsmåde til behandling af lægemiddelresistent cancer
BRPI0407097A (pt) Antagonista do casr
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BR0307588A (pt) Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença
RS53211B (en) PYRIDO [2,3-d] PYRIMIDINE DERIVATIVES, THEIR PRODUCTION, THEIR USE IN THERAPY
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
DK1970372T3 (da) Salte af 9-oxoacridin-10-eddikesyre med 1-alkylamino-1-deoxy-polyoler
DE602004026558D1 (de) Selektive nichtsteroidale glucocorticoid-rezeptor- modulatoren

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.